RECOMBINANT VACCINES AGAINST RETROVIRUS ASSOCIATED WITH AIDS
$0Z01FY2000AINIH
Niaid Extramural Activities
Investigators
Linked publications & trials
Paper 22234262Paper 19420086Paper 18160013Paper 18155813Paper 18048074Paper 17954572Paper 17698160Paper 17579577Paper 17499326Paper 17360078Paper 17201662Paper 16740288Paper 16725169Paper 16472543Paper 16409123Paper 16267024Paper 16083934Paper 16023165Paper 15858010Paper 15780866Paper 15731219Paper 15725752Paper 15710048Paper 15671796Paper 15650426Paper 15380355Paper 15367588Paper 15315833Paper 15249657Paper 15242543Paper 15242542Paper 15161069Paper 15096611Paper 15070762Paper 15047809Paper 15014500Paper 14963123Paper 14585221Paper 14551889Paper 12970455Paper 12869693Paper 12477888Paper 12477823Paper 12388710Paper 12097599Paper 12097576Paper 12021371Paper 12021347Paper 12009868Paper 11983252Paper 11752436Paper 11393868Paper 11333896Paper 11160750Paper 11134278Paper 10779808Paper 10775580Paper 10684290Paper 10684264
Abstract
Human immunodeficiency virus (HIV) infection is the determining factor in the development of acquired immunodeficiency syndrome (AIDS). At present there is no effective vaccine against this disease. The objectives of this project are to characterize HIV antigens, determine the targets of humoral and cell mediated immunity, and to use this information to develop candidate vaccines. We have constructed recombinant vaccinia viruses containing genetic information of HIV and the closely related simian immunodeficiency virus. These recombinant viruses have been used to prepare purified immunogens, monoclonal antibodies, targets for cytotoxic T cells and candidate vaccines
View original record on NIH RePORTER →